Finnish researchers studied the effectiveness of coronary vaccines.
Finns’ new folk vaccine Pfizer provides good protection against the awkward South African variant of the corona, says a new Finnish study.
However, the efficacy of the vaccine against the South African variant is clearly weaker than the efficacy against the original coronavirus or the British variant of the virus.
The vaccine generates antibodies that block the virus strain and variants of the virus.
“However, 92% of those vaccinated have neutralizing antibodies after two doses of vaccine, which are likely to provide at least some protection against the South African variant,” says a professor of virology at the University of Turku. Ilkka Julkunen says In Helsingin Sanomat.
Julkusen’s group has conducted the research together with researchers from the University of Helsinki.
The study followed 180 health care workers who had received a coronary vaccine.
The research result has not yet been peer-reviewed. The result has been published so-called as a pre-print.
In the HS, Julkunen estimates that the immunity to the South African variant also has the same effect on the Brazilian variant.
The transformations of South Africa and Brazil have caused concern in the world.
The University of South Africa, Witwatersrans, studied the effectiveness of the AstraZeneca vaccine. The vaccine was found to be only 10% effective against the South African variant.
Following the publication of the study, South Africa discontinued the use of AstraZeneca.
Read more: New study: AstraZeneca vaccine has only 10% efficacy against a viral variant in South Africa
Source site www.is.fi